A case control, multicentre, retrospective study assessing the association between 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccin and symptomatic SARS-CoV-2 infection with the Omicron and Delta variants
Latest Information Update: 21 Feb 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 14 Feb 2022 Results estimating the associations between symptomatic SARS-CoV-2 infection and receipt of BNT162b2, mRNA-1273, and Ad26.COV2.S by day since vaccination before and during Delta variant predominance, published in the JAMA: the Journal of the American Medical Association
- 31 Jan 2022 New trial record
- 12 Jan 2022 Results published in the JAMA: the Journal of the American Medical Association